ADVERTISEMENT
search.svg

Pharmacy News

In case you missed it: new study warns against acetaminophen use during pregnancy

A recent study published in Nature Reviews Endocrinology sheds light on the debate about acetaminophen use for pregnant women. After reviewing the medical literature on the topic going back 25 years, the research team is urging caution on the use of this common OTC during pregnancy because of the strong link associated with adverse neurological, urogenital, and reproductive outcomes in children.

New impurities lurking in some heart medications

Over the past few years, blood pressure medications have been recalled due to concerns about N-nitrosodimethylamine (NDMA), a probable carcinogen. But this may not be the only impurity to be worried about in these medications. As drug companies have addressed the NDMA issue, they have also found new potentially dangerous chemicals known as azido impurities.

USPSTF says aspirin recs to prevent heart attack or stroke should be changed

Health experts now believe that daily use of low-dose aspirin—once viewed as an inexpensive and effective prophylaxis against heart disease—has more potential harms than benefits.

APhA members unite to advocate for pharmacy patients

APhA members representing 31 states, Puerto Rico, and the District of Columbia gathered last week to flex their political muscles at the organization’s first virtual congressional conference. Over the course of the 3-day conference, participants got a crash course on crucial pharmacy practice legislation, worked with colleagues on advocacy strategy, and met with Members of Congress and their staff.

Walmart–Novo Nordisk insulin offers deep discounts to select few

Early last summer, Walmart announced the launch of a new private brand, cash-pay analog insulin, made by drug manufacturer Novo Nordisk. Sold under Walmart’s private ReliOn label, vials go for $72.88 each and FlexPens for $85.88 each. Walmart calculates that the products will save customers between 58% and 75% of the cash price for branded analog insulin products, which translates to savings of up to $101 per branded vial or $251 per package of branded FlexPens. But, for many who struggle with the day-to-day costs of living with diabetes, these brands may still be tough to afford. Other pharmacies or drug-maker patient assistance programs may offer more support to cash-strapped patients.

RSS
1345678910Last